Dopamine as the wind of the psychotic fire: New evidence from brain imaging studies

Journal of Psychopharmacology

Volumn 13, Issue 4, 1999, Pages 358-371

  Laruelle, Marc ^a,b   Abi Dargham, Anissa ^a  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Dopamine D2 receptors; Psychostimulants; Schizophrenia; SPECT

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR;

CONFERENCE PAPER; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0033399541     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119901300405     Document Type: Conference Paper

References (109)

1. 123I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35: 228-238
2. Abi-Dargham A, Gil R, Krystal J, Baldwin R, Seibyl J, Bowers M, van Dyck C, Charney D, Innis R, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761-767
3. Akimoto K, Hamamura T, Kazahaya Y, Akiyama K, Otsuki S (1990) Enhanced extracellular dopamine level may be the fundamental neuropharmacological basis of cross-behavioral sensitization between methamphetamine and cocaine - an in vivo dialysis study in freely moving rats. Brain Res 507: 344-346
4. Angrist B, van Kammen D P (1984) CNS stimulants as a tool in the study of schizophrenia. Trends Neurosci 7: 388-390
5. Angrist B, Rotrosen J, Gershon S (1980) Response to apomorphine, amphetamine and neuroleptics in schizophrenic subjects. Psychopharmacology (Berlin) 67: 31-38
6. Booij J, Korn P, Linszen D H, vanRoyen E A (1997) Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 24: 674-677
7. Breier A, Su T P, Saunders R, Carson R E, Kolachana B S, deBartolomeis A, Weinberger D R, Weisenfeld N, Malhotra A K, Eckelman W C, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574
8. Breier A, Adler C M, Weisenfeld N, Su T P, Elman I, Picken L, Malhotra A K, Pickar D (1998) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29: 142-147
9. Burt D R, Creese I, Snyder S S (1977) Antischizophrenic drugs: Chronic treatment elevates dopamine receptors binding in brain. Science 196: 326-328
10. 1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 730: 17-31
11. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179-186
12. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140-144
13. 18]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13: 24-42
14. Carson R E, Breier A, deBartolomeis A, Saunders R C, Su T P, Schmall B, Der M G, Pickar D, Eckelman W C (1997) Quantification of amphetamine-induced changes in [C-11]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 17: 437-447
15. Creese I, Burt D R, Snyder S H (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 19: 481-483
16. Cross A J, Crow T J, Ferrier I N, Johnstone E C, McCreadie R M, Owen F, Owens D G C, Poulter M (1983) Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J Neural Transm 18 (Suppl.): 265-272
17. Crow T J (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66-68
18. Daniel D G, Goldberg T E, Gibbons R D, Weinberger D R (1991) Lack of a bimodal distribution of ventricular size in schizophrenia: a Gaussian mixture analysis of 1056 cases and controls. Biol Psychiatry 30: 887-903
19. Dao-Castellana M H, Paillere-Martinot M L, Hantraye P, AttarLevy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot J L (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23: 167-174
20. Davis K L, Kahn R S, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486
21. DeJesus O T, Van Moffaert G J C, Dinerstein R J, Friedman A M (1986) Exogenous L-DOPA alters spiroperidol binding, in vivo, in the mouse striatum. Life Sci 39: 341-349
22. 18F]-N-methylspiperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7: 324-327
23. 11C-raclopride and positron emission tomography. J Neurosci 12: 3773-3780
24. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13: 350-356
25. Dewey S L, Smith G S, Logan J, Alexoff D, Ding Y S, King P, Pappas N, Brodie J D, Ashby C R (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15: 821-829
26. 11C]raclopride. Arch Gen Psychiatry 47: 213-219
27. 2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA 271: 204-208
28. 2-dopamine receptors in the monkey brain. Synapse 25: 321-325
29. 2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31: 154-162
30. Grace A A (1995) The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 37: 111-129
31. Grady E F, Bohm S K, Bunnett N W (1997) Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol 273: G586-G601
32. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci 15: 5222-5237
33. 2 receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51: 116-123
34. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U et al. (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346: 1130-1131
35. Hollingshead A B (1975) Four factor index of social status, Unpublished manuscript. New Haven, C T
36. 2 receptor in non-human primates. Synapse 10: 177-184
37. Janowsky D S, Davis J M (1976) Methylphenidate, dextroamphetamine and levamphetamine. Effects on schizophrenic symptoms. Arch Gen Psychiatry 33: 304-308
38. Kalivas P W (1993) Neurotransmitter regulation of dopamine neurons in the ventral tegumental area. Brain Res Rev 18: 75-113
39. Kalivas P W, Duffy P (1990) The effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumhens. Synapse 5: 48-58
40. Kalivas P W, Stewart J (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16: 223-244
41. Kalivas P W, Sorg B A, Hooks M S (1993) The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 4: 315-334
42. Karreman M, Moghaddam B (1996) The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem 66: 589-598
43. Kay S R, Fiszbein A, Opler L A (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schiz Bull 13: 261-276
44. Kazahaya Y, Akimoto K, Saburo O (1989) Subchronic methamphetamine treatment enhances methamphetamine-or cocaine-induced dopamine efflux in vivo. Biol Psychiatry 25: 903-912
45. 123I]IBZM SPECT measurement of amphetamine-induced dopamine release in healthy humans. Synapse 31: 302-308
46. 2 receptors. Synapse 15: 169-176
47. Koenig J A, Edwardson J M (1997) Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18: 276-287
48. Koepp M J, Gunn R M, Lawrence A D, Cunningham V J, Dagher A, Jones T, Brooks D J, Bench C J, Grasby P M (1998) Evidence for striatal dopamine release during a video game. Nature 393: 266-268
49. 3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Eur J Pharmacol 72: 397-402
50. Kuczenski R, Segal D (1989) Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9: 2051-2065
51. Lahti A C, Koffel B, LaPorte D, Tamminga C A (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19
52. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Kucl Med 42: 211-221
53. 123I]iomazenil. Eur J Pharmacol 230: 119-123
54. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14: 453-465
55. 123I]iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol 263: 39-51
56. Laruelle M, Abi-Dargham A, van Dyck C H, Rosenblatt W, ZeaPonce Y, Zoghhi S S, Baldwin R M, Charney D S, Hoffer P B, Kung H F, Innis R B (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182-1190
57. Laruelle M, Abi-Dargham A, van Dyck C H, Gil R, De Souza C D, Erdos J, Mc Cance E, Rosenblatt W, Fingado C, Zoghbi S S, Baldwin R M, Seibyl J P, Krystal J H, Charney D S, Innis R B (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240
58. Laruelle M, DSouza C D, Baldwin R M, Abi-Dargham A, Kanes S J, Fingado C L, Seibyl J P, Zoghbi S S, Bowers M B, Jatlow P, Charney D S, Innis R B (1997a) Imaging D-2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17: 162-174
59. Laruelle M, Iyer R N, Al-Tikriti M S, Zea-Ponce Y, Malison R, Zoghbi S S, Baldwin R M, Kung H F, Charney D S, Hoffer P B, Innis R B, Bradberry C W (1997b) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1-14
60. Lawrie S M, Abukmeil S S (1998) Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 172: 110-120
61. 3H-apomorphine in schizophrenic brains. Nature 274: 897-900
62. 2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90: 8861-8865
63. Lieberman J A, Kane J M, Gadaleta D, Brenner R, Lesser M S, Kinon B (1984) Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 141: 633-638
64. Lieberman J A, Kane J M, Alvir J (1987a) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91: 415-433
65. Lieberman J A, Kane J M, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J (1987b) Prediction of relapse in schizophrenia. Arch Gen Psychiatry 44: 597-603
66. Lieberman J A, Kinon B L, Loebel A D (1990) Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schiz Bull 16: 97-110
67. Lieberman J A, Sheitman B B, Kinon B J (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17: 205-229
68. 18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 9: 195-207
69. Mathe J M, Nomikos G G, Schilstrom B, Svensson T H (1998) Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens. J Neurosci Res 57: 583-592
70. Miller D W, Abercrombie E D (1996) Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40: 57-62
71. Mintun M A, Raichle M E, Kilbourn M R, Wooten G F, Welch M J (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 75: 217-227
72. Mukherjee J, Yang Z Y, Lew R, Brown T, Kronmal S, Cooper M D, Seiden L S (1997) Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography. Synapse 27: 1-13
73. Nelson M D, Saykin A J, Flashman L A, Riordan H J (1998) Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch Gen Psychiatry 55: 433-440
74. Owen F, Cross A J, Crow T J, Longden A, Poulter M, GJ R (1978) Increased dopamine-receptor sensitivity in schizophrenia. Lancet 2: 223-226
75. Patrick S L, Thompson T L, Walker J M, Patrik R L (1991) Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate nucleus. Brain Res 538: 343-346
76. Paulson P E, Robinson T E (1995) Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse 19: 56-65
77. Pettit H O, Pan H T, Parsons L H, Justice J B J (1990) Extracellular concentration of cocaine and dopamine are enhanced during chronic cocaine administration. J Neurochem 55: 798-804
78. 2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 1-123-IBZM single photon emission computerized tomography study. Br J Psychiatry 164: 16-26
79. Pycock C J, Kerwin R W, Carter C J (1980) Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286: 74-77
80. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve S E, Etienne P, Evans A C, Lal S, Shevell M, Savard G, Wong D F, Chouinard G, Gjedde A (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91: 11651-11654
81. Roberts A C, Desalvia M A, Wilkinson L S, Collins P, Muir J L, Everitt B J, Robbins T W (1994) 6-hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin card sort test: possible interactions with subcortical dopamine. J Neurosci 14: 2531-2544
82. Robinson P H, Jurson P A, Bennet J A, Bentgen K M (1988) Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res 462: 211-222
83. Robinson T E, Becker J B (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Review 11: 157-198
84. Ross S B (1991) Synaptic concentration of dopamine in the mouse striatum in relationship to the kinetic properties of the dopamine receptors and uptake mechanism. J Neurochem 56: 22-29
85. Ross S B, Jackson D M (1989a) Kinetic properties of the in vivo accumulation of the dopamine D-2 receptor antagonist raclopride in the mouse brain in vivo. Naunyn Schmiedeberg's Arch Pharmacol 340: 6-12
86. 3H](-)-N-n-propylnorapomorphine in the mouse brain. Naunyn Schmiedeberg's Arch Pharmacol 340: 13-20
87. Saunders R C, Kolachana B S, Bachevalier J, Weinberger D R (1998) Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature 393: 169-171
88. Schlaepfer T E, Pearlson G D, Wong D F, Marenco S, Dannals R F (1997) PET study of competition between intravenous cocaine and [C-11]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154: 1209-1213
89. Schooler N R, Keith S J, Severe J B, Matthews S M, Bellack A S, Glick I D, Hargreaves W A, Kane J M, Ninan P T, Frances A, Jacobs M, Lieberman J A, Mance R, Simpson G M, Woerner M G (1997) Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 54: 453-463
90. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133-152
91. Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188: 1217-1219
92. Seeman P, Grigoriadis D (1987) Dopamine receptors in brain and periphery. Neurochem Int 10: 1-25
93. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1: 5-15
94. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3: 96-97
95. 2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 86: 10156-10160
96. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U (1987) A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 401: 322-330
97. 2 dopamine receptor. J Biol Chem 257: 6351-6361
98. 1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. Proc Natl Acad Sci USA 91: 5720-5724
99. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18: 18-25
100. Spector S, Sjoerdsma A, Udenfriend S (1965) Blockade of endogenous norepinephrine synthesis by alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. J Pharmacol Exp Ther 147: 86-95
101. Svensson T H, Tung C S (1989) Local cooling of pre-frontal cortex induces pace-maker-like firing of dopamine neurons in rat ventral tegumental area in vivo. Acta Physiol Scand 136: 135-136
102. Udenfriend S, Nagatsu T, Zaltzman-Nirenberg P (1965) Inhibitors of purified beef adrenal tyrosine hydroxylase. Biochem Pharmacol 14: 837-847
103. Van der Werf J F, Sehens J B, Vaalburg W, Korf J (1986) In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism. Eur J Pharmacol 87: 259-270
104. van Kammen D P, Bunney W E Jr. Docherty J P, Marder S R, Ebert M H, Rosenblatt J E, Rayner J N (1982) d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry 139: 991-997
105. 11C]raclopride in the human brain. Synapse 16: 255-262
106. Volkow N D, Fowler J S, Gatley S J, Dewey S L, Wang G J, Logan J, Ding Y S, Franceschi D, Gifford A, Morgan A, Pappas N, King P (1999) Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse 31: 59-66
107. 2 dopamine receptors in drug-naive schizophrenics. Science 234: 1558-1563
108. 3H]raclopride binding in the rat brain. Synapse 9: 188-194
109. 2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65: 709-730